Anavex reports Q1 FY2026 net loss $5.7M; EU blarcamesine setback, re-examination ongoing

ANAVEX LIFE SCIENCES CORP.

2026-Q1 EPS reported -$0.06

Net loss of $5.7M ($0.06 per share) vs. $12.1M ($0.14) in Q1 FY2025; R&D expenses dropped to $4.7M from $10.4M.
Cash & equivalents $131.7M (up from $102.6M); company expects cash runway >3 years.
EU CHMP issued negative opinion for blarcamesine in early Alzheimer's; Anavex requested EMA re-examination (Dec 2025).
FDA Type C meeting in Jan 2026 showed interest; company will submit additional Phase IIb/III data for potential NDA.
Appointed Wolfgang Liedtke as SVP Global Head of Neurology; joined ACCESS-AD initiative.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.